No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Tilray Brands, Inc. is a globally operating company engaged in the comprehensive process of researching, cultivating, producing, marketing, and distributing medical cannabis products. Its international footprint spans Canada, the United States, Europe, Australia, New Zealand, and Latin America, among other regions. The enterprise functions through four key business segments: Cannabis, Distribution, Beverage Alcohol, and Wellness. Its diverse product range includes both medical and adult-use cannabis items, such as GMP-certified flowers, oils, vapes, edibles, and topicals. Additionally, Tilray acquires and resells pharmaceutical and general wellness products, and is involved in the production, marketing, sales, and distribution of alcoholic beverages, alongside hemp-based food and other health-focused offerings. These goods are sold under a wide array of brands, including Tilray, Aphria, Broken Coast, Symbios, B!NGO, The Batch, P'tite Pof, Dubon, Good Supply, Solei, Chowie Wowie, Canaca, RIFF, SweetWater, Breckenridge Distillery, Alpine Beer Company, and Green Flash. The company serves a varied customer base that includes retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and government entities, in addition to direct sales to consumers. Formerly known as Tilray, Inc., the company's headquarters are located in Leamington, Canada.
www.tilray.comNo one on the platform currently holds 2HQ.DE.
No tracked institution reports a position in 2HQ.DE as of their last filing.
No one on the platform has traded 2HQ.DE yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | 4.1% | 8.0% | ||||
| Profit Margin % | -266.3% | -133.8% | -70.0% | |||
| Free Cash Flow Margin % | -15.5% | -15.0% | -99.4% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $901M | +3.9% | $-0.02 | $-0.02–$-0.02 | — | 1 |
| 2028 | $936M | +3.9% | $-0.00 | $-0.00–$-0.00 | — | 1 |
| 2029 | $980M | +4.8% | $0.03 | $0.03–$0.03 | — | 1 |
| 2030 | $1.0B | +4.3% | $0.06 | $0.05–$0.06 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 1 of the last 7 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2025-10-09 | $-0.02 | $-0.00 | +88.8% |
| 2025-07-28 | $-0.02 | $-1.15 | -5433.0% |
| 2025-04-08 | $-0.04 | $-0.84 | -2219.4% |
| 2025-01-10 | $-0.03 | $-0.09 | -196.3% |
| 2024-10-10 | $-0.03 | $-0.04 | -14.3% |
| 2024-07-29 | $-0.02 | $-0.04 | -75.0% |
| 2024-04-09 | $-0.05 | $-0.11 | -140.0% |
| +1.34% |
| $1.9B |
| — |
| DRW3.DEDrägerwerk AG & Co. KGaA | $112.40 | +0.72% | $2.1B | — |
| DRW8.DEDrägerwerk AG & Co. KGaA | $86.20 | +2.62% | $2.1B | — |
Source: Financial Modeling Prep · peers by sector/industry